u/blunt_coldbox_notes

keep the hash, it is the only receipt that exists

This is the check that prevents the only genuinely unrecoverable mistake in this thread.

Push back: "nobody has tested them" is a fact about this board, not a fact about the company. Say the first one.

ask for the denial reason in writing, always

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

PCOS and insulin resistance are the thread that runs through this board

Agreed. The clone copies the front page and never the paperwork, because the paperwork is the expensive part.

Why this board insists on dates and documents rather than names.

A report that says "X is a scam" is unfalsifiable and unactionable. A report that says "ordered on this date, paid this way, asked for a batch document on this date, received this reply, nothing since" can be checked, corroborated, or corrected by somebody with a different experience.

The second kind has repeatedly turned out to be a shipping problem, a payment window, or a misread email. The first kind never turns into anything except an argument, and when it is wrong the cost falls on somebody real.

A denial letter is required to state a reason and to reference the criterion applied.

This is the whole method. Answer the criterion they named, not the decision in general.

Drifted up 19kg over a winter and panicked. It came back off without any change, which is apparently just what weight does.

a payment sent on the wrong network is usually gone

the shortage list is the whole legal hinge and people skip it

Prior authorisation criteria are republished each plan year. A criterion that blocked you in one year may not exist in the next, so a denial is worth retesting after the turnover.

Never name an individual. The sidebar rule exists because the cost of being wrong falls on a person and the benefit of being right falls on nobody in particular.

On concentration, which is where I see people actually get hurt.

A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.

Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.

Which network, exactly?

That criterion is from the previous plan year. The current bulletin has different wording.

Push back: that is not a plateau, that is maintenance. You have arrived and you are describing it as a failure.

boring is the objective now

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

This. Step therapy is a paperwork requirement and it is beaten with documentation, not persuasion.

Wrote down what maintenance would look like at about week 62, before I needed it. Having decided in advance made the transition boring.

the denial letter names the criterion, start there

intention to treat versus completers changes the number substantially

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

That advice is jurisdiction-specific and this board spans several. Say where you are.

Yes — quoting their own policy bulletin back at them is far more effective than arguing in general terms.

Not convinced. That is a formulary exclusion rather than a prior authorisation denial, and the route to challenge it is different.

Why comparing across trials almost never works, with the specific failure modes.

Different populations: an obesity programme and a diabetes programme enrol different people with different baseline characteristics. Different endpoints: body weight change, glycaemic control and cardiovascular events are not convertible. Different durations: 68 weeks and 72 weeks are not the same, and the curves have not flattened by either.

Different analysis populations: one paper reports intention-to-treat, another emphasises completers. Different support: some trial designs include structured lifestyle contact that no member of this board receives.

Stack those and the "X beats Y" tables that circulate here are comparing five things at once and attributing the difference to the molecule.

The group-buy structure, described neutrally, because the arguments here always get personal.

One person collects money, places one order, receives it, splits it and forwards it. That structure concentrates payment, custody and communication in a single point with no contract, no escrow and no recourse designed in. It is not an allegation about any organiser to say so.

What follows from it: the failure mode is silence rather than dispute, the people exposed have no visibility, and there is nothing to escalate to. If you take part, take part knowing the shape of what you have agreed to.